tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

LXRX Stock Latest News

Lexicon receives CRL for Zynquista
The FlyLexicon receives CRL for Zynquista
1d ago
LXRX
Lexicon price target lowered to $1.20 from $4 at Citi
PremiumThe Fly
Lexicon price target lowered to $1.20 from $4 at Citi
24d ago
LXRX
Lexicon announces completion of enrollment in Phase 2B PROGRESS study
PremiumThe Fly
Lexicon announces completion of enrollment in Phase 2B PROGRESS study
26d ago
LXRX
Lexicon price target lowered to $4 from $6 at H.C. Wainwright
PremiumThe Fly
Lexicon price target lowered to $4 from $6 at H.C. Wainwright
30d ago
LXRX
Lexicon to eliminate commercial organization, focus on clinical development
PremiumThe Fly
Lexicon to eliminate commercial organization, focus on clinical development
30d ago
LXRX
Lexicon Pharmaceuticals Appoints Ivan Cheung to Board
PremiumCompany AnnouncementsLexicon Pharmaceuticals Appoints Ivan Cheung to Board
1M ago
8K
LXRX
Lexicon announces data from four stories of sotagliflozin to be delivered
Premium
The Fly
Lexicon announces data from four stories of sotagliflozin to be delivered
1M ago
LXRX
Lexicon Pharmaceuticals Reports Q3 2024 Financial Results
Premium
Company Announcements
Lexicon Pharmaceuticals Reports Q3 2024 Financial Results
1M ago
LXRX
Lexicon reports Q3 EPS (18c), consensus (16c)
PremiumThe Fly
Lexicon reports Q3 EPS (18c), consensus (16c)
1M ago
LXRX
Lexicon Pharmaceuticals options imply 14.8% move in share price post-earnings
PremiumThe Fly
Lexicon Pharmaceuticals options imply 14.8% move in share price post-earnings
1M ago
LXRX
Lexicon announces JASN publishes sotagliflozin data
PremiumThe Fly
Lexicon announces JASN publishes sotagliflozin data
2M ago
LXRX
Lexicon to present data from two studies related to LX9851
PremiumThe Fly
Lexicon to present data from two studies related to LX9851
2M ago
LXRX
LXRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsLXRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
LXRX
Lexicon price target lowered to $6 from $10 at H.C. Wainwright
Premium
The Fly
Lexicon price target lowered to $6 from $10 at H.C. Wainwright
2M ago
LXRX
FDA panel votes 11-3 that Lexicon’s Zynquista benefits do not outweigh risks
Premium
The Fly
FDA panel votes 11-3 that Lexicon’s Zynquista benefits do not outweigh risks
2M ago
LXRX
FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting
PremiumThe Fly
FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting
2M ago
LXRX
Lexicon announces new analysis of Phase 3 SCORED trial
PremiumThe Fly
Lexicon announces new analysis of Phase 3 SCORED trial
2M ago
LXRX
Lexicon’s LX9211 progressing ahead of schedule, says H.C. Wainwright
PremiumThe Fly
Lexicon’s LX9211 progressing ahead of schedule, says H.C. Wainwright
2M ago
LXRX
Lexicon completes screening in Phase 2B progress study of LX9211
PremiumThe Fly
Lexicon completes screening in Phase 2B progress study of LX9211
2M ago
LXRX
Lexicon signs licensing agreement with Viatris for sotagliflozin
PremiumThe FlyLexicon signs licensing agreement with Viatris for sotagliflozin
2M ago
LXRX
VTRS
Lexicon receives $25M upfront from Viatris for exclusive sotagliflozin license
Premium
The Fly
Lexicon receives $25M upfront from Viatris for exclusive sotagliflozin license
2M ago
LXRX
VTRS
Lexicon to present Phase 3 trial design for sotagliflozin in HCM
Premium
The Fly
Lexicon to present Phase 3 trial design for sotagliflozin in HCM
3M ago
LXRX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >